Format

Send to

Choose Destination
Cell Metab. 2016 Jun 14;23(6):959-960. doi: 10.1016/j.cmet.2016.05.017.

Opposing Effects of Antidiabetic Interventions on Malignant Growth and Metastasis.

Author information

1
Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany; Division of Metabolic Diseases, Department of Medicine, Technische Universität München, 80333 Munich, Germany; German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany.
2
German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany; Division of Endocrinology, University Hospital Leipzig, 04103 Leipzig, Germany.
3
Department of Health Sciences and Technology, Swiss Federal Institute of Technology Zurich (ETHZ), 8092 Zurich, Switzerland. Electronic address: michael-ristow@ethz.ch.

Abstract

Type 2 diabetes is associated with increased risk of malignancies, whereas antidiabetic interventions like physical exercise or metformin reduce cancer incidence. A recent publication shows that one diabetes treatment approach, namely incretin-related DPP4 inhibitors, increases metastatic capacity by activating the antioxidant transcription factor NRF2 to decrease reactive oxygen species (ROS) levels.

PMID:
27304493
DOI:
10.1016/j.cmet.2016.05.017
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center